Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers

[1]  Anand K. Narayan,et al.  Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study , 2016, Breast Cancer Research and Treatment.

[2]  Ellen Warner,et al.  Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis , 2016, British Journal of Cancer.

[3]  T. Helbich,et al.  Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Hooning,et al.  Should we screen BRCA1 mutation carriers only with MRI? A multicenter study , 2014, Breast Cancer Research and Treatment.

[5]  E. Morris,et al.  MR Imaging Features of Triple‐Negative Breast Cancers , 2013, The breast journal.

[6]  R. Warren,et al.  Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[7]  Y. Miki.  [Cellular functions of BRCA genes - from basic science to therapeutics]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[8]  G. Hortobagyi,et al.  Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer , 2011, Cancer.

[9]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Maximilian Reiser,et al.  Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Oosterwijk,et al.  Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.

[12]  C. D'Orsi,et al.  Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. , 2010, Journal of the American College of Radiology : JACR.

[13]  Fiona J Gilbert,et al.  Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. , 2009, Radiology.

[14]  G. Hortobagyi,et al.  High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers , 2009, Cancer Prevention Research.

[15]  J. Thigpen.  Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers , 2009 .

[16]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Kuhl,et al.  Mammographic, US, and MR imaging phenotypes of familial breast cancer. , 2008, Radiology.

[19]  A. Howell,et al.  Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family , 2008, BMC Cancer.

[20]  R. Jong,et al.  Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[21]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[22]  Michael Waller,et al.  Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial , 2006, The Lancet.

[23]  L. Liberman,et al.  Determination of the Presence and Extent of Pure Ductal Carcinoma in Situ by Mammography and Magnetic Resonance Imaging , 2005, The breast journal.

[24]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[25]  J. Klijn,et al.  Efficacy of magnetic resonance imaging and mammography for breast cancer screening in women with a familial or genetic predisposition , 2005 .

[26]  S. Pinder,et al.  Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. , 2004, Clinical radiology.

[27]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[28]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[29]  C. Zuiani,et al.  Ductal carcinoma in situ: is there a role for MRI? , 2002, Journal of experimental & clinical cancer research : CR.

[30]  M. Schnall,et al.  MR imaging of ductal carcinoma in situ. , 1997, Radiology.

[31]  C. Boetes,et al.  False-negative MR imaging of malignant breast tumors , 1997, European Radiology.

[32]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.